title: The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial.
abstract: We compared the efficacy and safety of a new fixed combination of timolol 0.5%/odorzolamide 20%/brimonidine 0.2% in ophthalmic solution versus a fixed combination of timolol 0.5%/dorzolamide 2% in patients with open-angle glaucoma or ocular hypertension. The fixed triple combination was significantly more efficient in mean intraocular pressure reduction from baseline throughout the six-month follow-up.
authors.affiliation: Clinical Research Department, Laboratorios Sophia, S.A. de C.V. Guadalajara, Jalisco, Mexico. drbvista@sophia.com.mx
authors.forename: Leopoldo Martín
authors.initials: LM
authors.lastname: Baiza-Durán
authors.forename: Jaime
authors.initials: J
authors.lastname: Alvarez-Delgado
authors.forename: Angélica Yussett
authors.initials: AY
authors.lastname: Contreras-Rubio
authors.forename: Javier
authors.initials: J
authors.lastname: Medrano-Palafox
authors.forename: Anel
authors.initials: A
authors.lastname: De Luca-Brown
authors.forename: Homero
authors.initials: H
authors.lastname: Casab-Rueda
authors.forename: Marco Antonio
authors.initials: MA
authors.lastname: Cortés-Gastélum
authors.forename: Miguel Jorge
authors.initials: MJ
authors.lastname: Garcidueñas-Mejía
authors.forename: Pedro
authors.initials: P
authors.lastname: Gómez-Bastar
authors.forename: Félix
authors.initials: F
authors.lastname: Gil-Carrasco
authors.forename: Curt
authors.initials: C
authors.lastname: Hartleben-Matkin
authors.forename: Jesús
authors.initials: J
authors.lastname: Jiménez-Román
authors.forename: Miguel Luis
authors.initials: ML
authors.lastname: Moreno-Marín
authors.forename: José Antonio
authors.initials: JA
authors.lastname: Paczka-Zapata
authors.forename: Gustavo
authors.initials: G
authors.lastname: Velasco-Gallegos
authors.forename: Mario
authors.initials: M
authors.lastname: Vergara-Sinta
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage; D000959:Antihypertensive Agents / Q000008:administration & dosage; D000068438:Brimonidine Tartrate; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy / Q000503:physiopathology; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D011810:Quinoxalines / Q000008:administration & dosage*; D013449:Sulfonamides / Q000008:administration & dosage*; D013876:Thiophenes / Q000008:administration & dosage*; D013997:Time Factors; D013999:Timolol / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000316:Adrenergic alpha-Agonists; D000959:Antihypertensive Agents; D002257:Carbonic Anhydrase Inhibitors; D004338:Drug Combinations; D009883:Ophthalmic Solutions; D011810:Quinoxalines; D013449:Sulfonamides; D013876:Thiophenes; D000068438:Brimonidine Tartrate; D013999:Timolol; C062765:dorzolamide